134 related articles for article (PubMed ID: 29851225)
1. Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and noninmates.
Marco A; Roget M; Cervantes M; Forné M; Planella R; Miquel M; Ortiz J; Navarro M; Gallego C; Vergara M;
J Viral Hepat; 2018 Nov; 25(11):1280-1286. PubMed ID: 29851225
[TBL] [Abstract][Full Text] [Related]
2. Multicenter study on the discontinuation and efficacy of chronic hepatitis C treatment in the Spanish penitentiary population (EPIBAND study).
Juan Jd; de la Hoya PS; Marco A; Antón JJ; Faraco I; Yllobre C; Pozo E; Hoyos C
Eur J Gastroenterol Hepatol; 2014 Oct; 26(10):1083-9. PubMed ID: 25076064
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand.
Supanan R; Han WM; Harnpariphan W; Ueaphongsukkit T; Ubolyam S; Sophonphan J; Tangkijvanich P; Thanprasertsuk S; Avihingsanon A;
J Acquir Immune Defic Syndr; 2021 Dec; 88(5):465-469. PubMed ID: 34757974
[TBL] [Abstract][Full Text] [Related]
4. Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study.
Marco A; Antón JJ; Trujols J; Saíz de la Hoya P; de Juan J; Faraco I; Caylà JA;
BMC Infect Dis; 2015 Aug; 15():355. PubMed ID: 26286450
[TBL] [Abstract][Full Text] [Related]
5. Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002-2016.
Marco A; Guerrero RA; Vergara M; Gallego C; Solé C; Planella R; Vaz ME; Teixidó N; Sastre A; Touzón C; da Silva A; Almada G; Ruíz A; Caylà JA; Turu E
Int J Drug Policy; 2019 Oct; 72():189-194. PubMed ID: 31160156
[TBL] [Abstract][Full Text] [Related]
6. The effect of direct-acting antiviral regimens and telemedicine on the treatment of inmates with hepatitis C virus infection in Israeli prisons.
Richter V; Goldstein L; Cohen DL; Bermont A; Zelnik Yovel D; Madar M; Rabinovitch R; Shirin H; Broide E
Sci Prog; 2022; 105(2):368504221105173. PubMed ID: 35722762
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
[TBL] [Abstract][Full Text] [Related]
8. HCV infected prisoners: should they be still considered a difficult to treat population?
Iacomi F; Iannicelli G; Franceschini A; Migliorisi P; Rosati S; Piselli P; Scognamiglio P; De Carli G; Marcellini S; Palmieri F
BMC Infect Dis; 2013 Aug; 13():374. PubMed ID: 23945309
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.
Salmerón J; Vinaixa C; Berenguer R; Pascasio JM; Sánchez Ruano JJ; Serra MÁ; Gila A; Diago M; Romero-Gómez M; Navarro JM; Testillano M; Fernández C; Espinosa D; Carmona I; Pons JA; Jorquera F; Rodriguez FJ; Pérez R; Montero JL; Granados R; Fernández M; Martín AB; Muñoz de Rueda P; Quiles R;
World J Gastroenterol; 2015 Aug; 21(30):9163-74. PubMed ID: 26290644
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
[TBL] [Abstract][Full Text] [Related]
11. [Effectiveness of second-generation direct-acting antivirals in chronic hepatitis C].
Juanbeltz R; Zozaya JM; Repáraz J; Castilla J; Sarobe MT; Úriz Otano JI; Gracia Ruiz de Alda M; San Miguel R
An Sist Sanit Navar; 2017 Apr; 40(1):57-66. PubMed ID: 28534541
[TBL] [Abstract][Full Text] [Related]
12. Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm.
Cuadrado A; Llerena S; Cobo C; Pallás JR; Mateo M; Cabezas J; Fortea JI; Alvarez S; Pellón R; Crespo J; Echevarría S; Ayesa R; Setién E; Lopez-Hoyos M; Crespo-Facorro B; Agüero J; Chueca N; Garcia F; Calleja JL; Crespo J
Am J Gastroenterol; 2018 Nov; 113(11):1639-1648. PubMed ID: 29946175
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic hepatitis C in Canadian prison inmates.
Farley JD; Wong VK; Chung HV; Lim E; Walters G; Farley TA; Yoshida EM
Can J Gastroenterol; 2005 Mar; 19(3):153-6. PubMed ID: 15776135
[TBL] [Abstract][Full Text] [Related]
14. Elimination of hepatitis C virus in a prison: An 18-year experience.
Nogales-Garcia M; Parraza Diez N; Vargas Axpe A; Velasco Garcia R; Larrabeiti-Etxebarria A; Roy Lopez-Cano I; Atrio Alvarez I; Lopez de Arcaute Trincado A; Fernandez Lopez de Vicuña EM; Saez de Adana Arroniz E; Martínez Martínez C; Portu Zapirain J
Enferm Infecc Microbiol Clin (Engl Ed); 2024 May; 42(5):236-241. PubMed ID: 37117143
[TBL] [Abstract][Full Text] [Related]
15. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
Iqbal S; Yousuf MH; Yousaf MI
World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
[TBL] [Abstract][Full Text] [Related]
16. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.
Ji F; Wei B; Yeo YH; Ogawa E; Zou B; Stave CD; Li Z; Dang S; Furusyo N; Cheung RC; Nguyen MH
Aliment Pharmacol Ther; 2018 Mar; 47(5):550-562. PubMed ID: 29327780
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C.
Marco A; Esteban JI; Solé C; da Silva A; Ortiz J; Roget M; Sarriera C; Teixidó N; Guerrero RA; Caylà JA
J Hepatol; 2013 Jul; 59(1):45-51. PubMed ID: 23523577
[TBL] [Abstract][Full Text] [Related]
18. Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience.
Haridy J; Wigg A; Muller K; Ramachandran J; Tilley E; Waddell V; Gordon D; Shaw D; Huynh D; Stewart J; Nelson R; Warner M; Boyd M; Chinnaratha MA; Harding D; Ralton L; Colman A; Liew D; Iyngkaran G; Tse E;
J Viral Hepat; 2018 Nov; 25(11):1287-1297. PubMed ID: 29888827
[TBL] [Abstract][Full Text] [Related]
19. Predictive variables of sustained virological response after early discontinuation of triple therapy with telaprevir for genotype-1 HCV infection.
Acero Fernández D; Morillas Cunill R; Ferri Iglesias MJ; Torras Collell X; Vergara Gómez M; Zaragoza Velasco N; López Nuñez C; Forné Bardera M; Delgado Gómez M; Barenys Lacha M; Torres Salinas M; Villar Fernández M; Durández Lázaro R; Mariño Mendez Z
Gastroenterol Hepatol; 2016; 39(6):377-84. PubMed ID: 26614733
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of chronic hepatitis C virus infection. A study of best predictors for response].
Vanegas NO; Román JL; Febles MH; Sánchez CG; Suárez JM; Martínez ER; Hernández LO; López MJ
Rev Esp Quimioter; 2011 Dec; 24(4):198-203. PubMed ID: 22173189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
